New llama-derived nanobodies enable selective detection and capture of Z-DNA

Z-DNA is a left-handed DNA conformation that forms transiently at susceptible genomic sequences during processes such as negative supercoiling and active transcription. In the cytoplasm, the innate immune receptor ZBP1 senses Z-form nucleic acids (Z-NAs, which could be DNA or RNA), triggering type I interferon production and programmed cell death. Viral infections, endogenous repetitive-element-derived RNAs, and oxidized mitochondrial DNA can generate Z-NAs, nominating them as ZBP1 agonists. Conversely, ADAR1 is proposed to recognize and edit endogenous Z-RNAs, thereby muting inappropriate innate immune responses. Both proteins engage Z-NAs through Zα domains, which are evolutionarily conserved across vertebrates. Progress in defining Z-NA biology has been limited by near-exclusive reliance on the Z22 monoclonal antibody, the field's principal detection reagent. To expand the availability of distinct, validated anti-Z-NA affinity reagents, we generated and characterized llama-derived nanobodies. Llamas were immunized with brominated poly(dG:dC) DNA, and four recombinant nanobodies (nZ6, nZ6.2, nZ10, and nZ11) that bound the antigen were identified through affinity enrichment and mass spectrometry-guided discovery. The nanobodies selectively recognized Z-DNA in biochemical assays and displayed nanomolar affinities, while homodimerized nZ6.2 achieved picomolar binding. Unlike Zα domains, nZ6.2 does not induce B-to-Z transitions, indicating recognition of pre-existing Z-DNA and immobilized nZ6.2 selectively co-immunoprecipitated ADAR1 and ZBP1 with Z-DNA but not B-DNA. Furthermore, nZ6.2 detected Z-DNA-related structures in a human keratinocyte cell line and in neutrophils from patients with systemic lupus erythematous, producing staining patterns overlapping those of Z22. These renewable, engineerable binders provide orthogonal reagents for investigating Z-NA biology, interferon signaling, and autoimmune disease.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-19
DOI
https://doi.org/10.64898/2026.11.17.765674
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

New llama-derived nanobodies enable selective detection and capture of Z-DNA

John LaCava, Martin S. Taylor, Jonah Da Silva, Bryant D. Miller et al.
bioRxiv (Cold Spring Harbor Laboratory)
Monoclonal and Polyclonal Antibodies Research
preprint

New llama-derived nanobodies enable selective detection and capture of Z-DNA

John LaCava, Martin S. Taylor, Jonah Da Silva, Bryant D. Miller, Peter C. Fridy, Hua Jiang, Mathias Ingemann Nielsen, Tomas Mustelin, Joanne Michelle Kahlenberg, Michael P. Rout, Manolis Pasparakis, Brian T. Chait, Laurens Wachsmuth, Mohammad Pourshamsi, Jonathan Kittel
preprint en

Abstract

Z-DNA is a left-handed DNA conformation that forms transiently at susceptible genomic sequences during processes such as negative supercoiling and active transcription. In the cytoplasm, the innate immune receptor ZBP1 senses Z-form nucleic acids (Z-NAs, which could be DNA or RNA), triggering type I interferon production and programmed cell death. Viral infections, endogenous repetitive-element-derived RNAs, and oxidized mitochondrial DNA can generate Z-NAs, nominating them as ZBP1 agonists. Conversely, ADAR1 is proposed to recognize and edit endogenous Z-RNAs, thereby muting inappropriate innate immune responses. Both proteins engage Z-NAs through Zα domains, which are evolutionarily conserved across vertebrates. Progress in defining Z-NA biology has been limited by near-exclusive reliance on the Z22 monoclonal antibody, the field's principal detection reagent. To expand the availability of distinct, validated anti-Z-NA affinity reagents, we generated and characterized llama-derived nanobodies. Llamas were immunized with brominated poly(dG:dC) DNA, and four recombinant nanobodies (nZ6, nZ6.2, nZ10, and nZ11) that bound the antigen were identified through affinity enrichment and mass spectrometry-guided discovery. The nanobodies selectively recognized Z-DNA in biochemical assays and displayed nanomolar affinities, while homodimerized nZ6.2 achieved picomolar binding. Unlike Zα domains, nZ6.2 does not induce B-to-Z transitions, indicating recognition of pre-existing Z-DNA and immobilized nZ6.2 selectively co-immunoprecipitated ADAR1 and ZBP1 with Z-DNA but not B-DNA. Furthermore, nZ6.2 detected Z-DNA-related structures in a human keratinocyte cell line and in neutrophils from patients with systemic lupus erythematous, producing staining patterns overlapping those of Z22. These renewable, engineerable binders provide orthogonal reagents for investigating Z-NA biology, interferon signaling, and autoimmune disease.

bioRxiv (Cold Spring Harbor Laboratory)
Harvard University (US), University of Cologne (DE), University of Washington (US), Brown University (US), University of Michigan (US), Michigan Medicine (US), Dana-Farber Cancer Institute (US), University of Nebraska Medical Center (US), Rockefeller University (US)
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon